Eisai and Purdue Pharma have announced six-month results from the SUNRISE 2 Phase III clinical study evaluating the efficacy and safety of lemborexant.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.